<DOC>
	<DOCNO>NCT02222454</DOCNO>
	<brief_summary>The primary objective case series evaluate safety tolerability KLOX BioPhotonic System adjunctive therapy Standard Of Care ( SOC ) patient stage II III pressure ulcer .</brief_summary>
	<brief_title>Safety Evaluation KLOX BioPhotonic System Stage II III Pressure Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Pressure Ulcer</mesh_term>
	<criteria>Male female 18 year age old ; The subject legal guardian must sign informed consent form ; Female child bear potential must negative pregnancy test result Baseline male female patient must willing adhere medicallyaccepted birth control method course study ; Willingness return study visit ; Stage II III pressure ulcer ( per NPUAP Staging Guidelines ) , present 4 week ( Screening visit ) , locate ischial , trochanteric , coccygeal , thoracic abdominal region . Lower extremity pressure ulcer , heel ulcer , acceptable provide diabetic foot ulcer rule patient diabetes . Surface dimension ulcer must 2 64 cm2 inclusive long diameter must exceed 10 cm . Depth must exceed 5 cm ; Wound area change +/ 30 % Screening visit Week 1/Visit 1 ( treatment ) . Pressure ulcer present 18 month ; The ulcer treat planned operative debridement ; The ulcer significant necrotic tissue ( e.g. , 20 % ulcer area ) ; Major uncontrolled medical disorder ( ) serious cardiovascular , renal , liver pulmonary disease , lupus , palliative care sickle cell anemia ; Severe significant hypoalbuminemia ( albuminemia &lt; 30 g/L , and/or prealbumin &lt; 5 mg/dL ) , hypoproteinemia ( proteinemia &lt; 55g/L ) ; Patient moderate severe anemia ( Hb &lt; 90g/L ) ; Patient currently treat active malignant disease ; Patient history malignancy within wound ; Patient history radiation therapy wound region ; Patient prior diagnosis active malignant disease less 1 year diseasefree ; Patient know osteomyelitis active cellulitis ; Patients immunosuppressed high dose chronic steroid use ; Patients systemic corticosteroid ( completion corticosteroid course least 30 day prior study enrolment require ) ; Patient active systemic infection ( note patient however eligible rescreening systemic infection subside ) ; Patients severely uncontrolled diabetes mellitus ( define A1C &gt; 12 % ) ; Dermatologic comorbid disease ( e.g. , cutis laxa collagen vascular disease ) ; Active bleeding ; Pregnancy , breast feeding ; Patients bleed diathesis ; Patients Warfarin IV Heparin ; The subject physical psychiatric condition Investigator 's opinion would warrant exclusion study prevent subject completing study ( e.g. , severe morbid obesity , recent hip fracture , suspect noncompliance , etc . ) ; Patients ulcer burn ( exposure high heat ) , venous ulcer diabetic foot ulcer ; Concurrent disease drug know induce severe photosensitivity skin , porphyria ; Patient receive biologicalbased therapy wound within 3 month Screening ; Concurrent participation another clinical trial involve investigational drug device wound interfere study ; Previous participation interventional wound heal clinical investigation within 60 day prior Screening visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>